Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Follow-Up Questions
Who is the CEO of Caribou Biosciences Inc?
Dr. Rachel Haurwitz is the President of Caribou Biosciences Inc, joining the firm since 2021.
What is the price performance of CRBU stock?
The current price of CRBU is $2.41, it has decreased 0.59% in the last trading day.
What are the primary business themes or industries for Caribou Biosciences Inc?
Caribou Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Caribou Biosciences Inc market cap?
Caribou Biosciences Inc's current market cap is $224.9M
Is Caribou Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Caribou Biosciences Inc, including 5 strong buy, 7 buy, 2 hold, 0 sell, and 5 strong sell
